<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **CSLL-D 1 of 6**  
Internal request  
In response to the FDA approval of ibrutinib + obinutuzumab as an option for treatment naïve patients with CLL/SLL based on the data from iLLUMINATE study, the panel voted on the addition of this regimen for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients ≥65 y and younger patients with significant comorbidities. | In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + obinutuzumab, the panel consensus was to include ibrutinib + obinutuzumab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients age ≥65 y and younger patients with significant comorbidities with a category 2B recommendation, other recommended regimen.  
NO  
ABSTAIN  
ABSENT |
| **External request**  
Submission request from Pharmacyclics LLC and Janssen Biotech, Inc. for first-line therapy for CLL/SLL without del(17p)/TP53 mutation for <65 y without significant comorbidities: Ibrutinib + rituximab: Recommend as Category 1, preferred regimen, for patients with unmutated and mutated IGHV. | In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + rituximab, the panel consensus was to include ibrutinib + rituximab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for patients <65 y without significant comorbidities with a category 2B recommendation, other recommended regimen.  
NO  
ABSTAIN  
ABSENT |